Synaptic Mechanisms Underlying Rapid Antidepressant Action of Ketamine
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Recent clinical studies have demonstrated that a single subpsychotomimetic dose of ketamine, an ionotropic glutamatergic N-methyl-D-aspartate (NMDA) receptor antagonist, produces a rapid antidepressant response in patients with major depressive disorder, with effects lasting up to 2 weeks. Despite enthusiasm about this unexpected efficacy of ketamine, its widespread use as a fast-acting antidepressant in routine clinical settings is curtailed by its abuse potential as well as possible psychotomimetic effects. However, the ability of ketamine to produce a rapid and long-lasting antidepressant response in patients with depression provides a unique opportunity for investigation of mechanisms that mediate these clinically relevant behavioral effects. From a mechanistic perspective, it is easy to imagine how activation of NMDA receptors may trigger cellular and behavioral responses; it is relatively more difficult, however, to envision how transient blockade of one of the key pathways for neuronal communication produces a persistent beneficial effect. The authors discuss recent work linking ketamine's mechanism of action to homeostatic synaptic plasticity processes activated after suppression of NMDA-mediated glutamatergic neurotransmission. They focus on their recent work demonstrating that ketamine-mediated blockade of NMDA receptors at rest deactivates eukaryotic elongation factor 2 (eEF2) kinase, resulting in reduced eEF2 phosphorylation and desuppression of rapid dendritic pr…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
A Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375
Self-citationmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Homeostatic plasticity in the developing nervous system
Turrigiano, G. G., & Nelson, S. B. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1327 · Cited by 2,485
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Self-citationMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression
Shirayama, Y., Chen, A. C.-H., Nakagawa, S., Russell, D. S., & Duman, R. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03251.2002 · Cited by 1,654
The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission
Popoli, M., Yan, Z., McEwen, B. S., & Sanacora, G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3138 · Cited by 1,393
Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., & Santoro, M. G. (2000) · Nature · doi:10.1038/47520 · Cited by 1,310
Research works printed but not linked: 2
- Schwartz PH, 1991, Res Commun Chem Pathol Pharmacol, 73, 181
- Gómez-Galán M, Mol Psychiatry
Cited by
Items 101–200 of 276
Role of BDNF in the development of an OFC-amygdala circuit regulating sociability in mouse and human
Li, A., Jing, D., Dellarco, D. V., Hall, B. S., Yang, R., Heilberg, R. T., Huang, C., Liston, C. M., Casey, B. J., & Lee, F. S. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0422-4 · Cited by 45
Ketamine and other glutamate receptor modulators for depression in adults
Amit, B. H., Caddy, C., McCloud, T. L., Rendell, J. M., Hawton, K., Diamond, P. R., McShane, R., & Cipriani, A. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011612 · Cited by 43
Ketamine and Calcium Signaling—A Crosstalk for Neuronal Physiology and Pathology
Lisek, M., Żylińska, L., & Boczek, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218410 · Cited by 44
“An excessive release of glutamate induced by Ca2+ dysregulation within the presynaptic compartment causes a prolonged activation of postsynaptic AMPA receptors and some long-term action of ketamine induced by altered ion homeostasis can modify synaptic transmission, due to altered expression of genes coding components…”
BackgroundSala, N., Paoli, C., Bonifacino, T., Mingardi, J., Schiavon, E., Via, L. L., Milanese, M., Tornese, P., Datusalia, A. K., Rosa, J., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.759626 · Cited by 43
den Hartog, C. R., Beckley, J. T., Smothers, C. T., Lench, D. H., Holseberg, Z. L., Fedarovich, H., Gilstrap, M. J., Homanics, G. E., & Woodward, J. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080541 · Cited by 41
“supporting a role for NMDA receptors in emotional processing [39–41].”
BackgroundNovel Targets to Treat Depression: Opioid-Based Therapeutics
Browne, C. A., Jacobson, M. L., & Lucki, I. (2020) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000242 · Cited by 40
Neurobiological aspects of suicide and suicide attempts in bipolar disorder
Mathews, D., Richards, E., Niciu, M., Ionescu, D., Rasimas, J., & Zarate, C. (2013) · Translational Neuroscience · doi:10.2478/s13380-013-0120-7 · Cited by 39
Ketamine rescues anhedonia by cell-type- and input-specific adaptations in the nucleus accumbens
Lucantonio, F., Roeglin, J., Li, S., Lu, J., Shi, A., Czerpaniak, K., Fiocchi, F. R., Bontempi, L., Shields, B. C., Zarate, C. A., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.02.021 · Cited by 39
“70 Additionally, disrupting ketamine-induced spine formation blocked its impact on motivated escape behavior but not on sucrose preference, pointing to a specific role of prefrontal spinogenesis in sustaining certain behavioral repertoires.”
Weise, D., Mann, J., Rumpf, J., Hallermann, S., & Claßen, J. (2016) · Cerebral Cortex · doi:10.1093/cercor/bhw212 · Cited by 39
Current Status of Ketamine and Related Compounds for Depression: (ASCP Corner)
Mathews, D. C., & Zarate, Jr. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13ac08382 · Cited by 35
The Potential of KCNQ Potassium Channel Openers as Novel Antidepressants
Costi, S., Han, M., & Murrough, J. W. (2022) · CNS Drugs · doi:10.1007/s40263-021-00885-y · Cited by 39
“Since ketamine was first tested as a treatment for depression, scientific investigations have examined the role of the glutamate system in the neurobiology of MDD and its potential as a target for novel therapeutics, paving the way for the possibility of more direct pharmacological targets [12, 13].”
BackgroundRapid antidepressant effects: moving right along
Martinowich, K., Jimenez, D. V., Zarate, C. A., & Manji, H. K. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.55 · Cited by 32
Wesseling, H., Rahmoune, H., Tricklebank, M., Guest, P. C., & Bahn, S. (2015) · Journal of Proteome Research · doi:10.1021/pr5009493 · Cited by 37
Afzal, M., Kazmi, I. A., Khan, R., Rana, P., Kumar, V., Al-Abbasi, F. A., Zamzami, M. A., & Anwar, F. (2017) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2017.05.006 · Cited by 37
“Ibuprofen act as nonselective drug which inhibits COX enzyme [12-13].”
BackgroundMingardi, J., La Via, L., Tornese, P., Carini, G., Trontti, K., Seguini, M., Tardito, D., Bono, F., Fiorentini, C., Elia, L., et al. (2021) · Neurobiology of Stress · doi:10.1016/j.ynstr.2021.100381 · Cited by 36
“A key role has been attributed to the interaction between genetic background and environmental events, with stress representing the major recognized environmental risk factor for the onset of depressive disorders (Keers and Uher, 2012; Krishnan and Nestler, 2008; Popoli et al., 2011).”
BackgroundLeung, E., Lau, E. W., Liang, A., de Dios, C., Suchting, R., Östlundh, L., Masdeu, J. C., Fujita, M., Sanches, M., Soares, J. C., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01410-9 · Cited by 36
“While there are a few studies on ketamine on synaptic proteins [98], the evidence of ketamine affecting synaptic protein levels is still controversial, with some studies pointing to increased levels of synaptic proteins [93, 99] while other studies show reduced levels [100, 101].”
BackgroundGruenbaum, B. F., Zlotnik, A. A., Frenkel, A., Fleidervish, I. A., & Boyko, M. (2022) · Metabolites · doi:10.3390/metabo12050459 · Cited by 37
“Often, treatments do not begin to work until weeks or months of administration [6].”
BackgroundZarate, C. A., & Machado-Vieira, R. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.249 · Cited by 33
Emnett, C. M., Eisenman, L. N., Jayaram, M., Taylor, A., Doherty, J., Paul, S. M., Zorumski, C. F., & Mennerick, S. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13007 · Cited by 34
“This recent study further extends the idea that blockade of spontaneous transmission underlies ketamine’s antidepressant behavioural effect (Autry et al., 2011; Kavalali and Monteggia, 2012).”
BackgroundHistoire de la kétamine : une molécule ancienne qui a toujours la cote
Daré, B. L., Pelletier, R., Morel, I., & Gicquel, T. (2021) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2021.04.005 · Cited by 33
Pradhan, B., Parikh, T., Makani, R. D., & Sahoo, M. (2015) · Depression Research and Treatment · doi:10.1155/2015/842817 · Cited by 33
“It is also possible that ketamine may cause inhibition of the activities of the GABAergic (inhibitory) interneurons thereby increasing the overall excitatory postsynaptic transmission [1], which may lead to its antidepressant effects.”
BackgroundBaek, J. H., Kang, E., Fava, M., Mischoulon, D., Nierenberg, A. A., Lee, D., Heo, J.-Y., & Jeon, H. J. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.08.009 · Cited by 32
“Administration of ketamine produces a rapid antidepressant response mediated by BDNF signaling (Kavalali and Monteggia, 2012), which suggests that the action of antidepressants could be mediated by its action on the BDNF system.”
BackgroundNMDA Receptor Antagonist Ketamine Impairs Feature Integration in Visual Perception
Meuwese, J. D. I., van Loon, A. M., Scholte, H. S., Lirk, P. B., Vulink, N. C. C., Hollmann, M. W., & Lamme, V. A. F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079326 · Cited by 32
“increase of synaptogenesis [68–70].”
Ren, Z., Wang, M., Aldhabi, M., Zhang, R., Liu, Y., Liu, S., Tang, R., & Chen, Z. (2021) · Neurobiology of Stress · doi:10.1016/j.ynstr.2021.100422 · Cited by 31
“What’s more, ketamine has rapid and lasting anti-depressive effects through influencing synaptic plasticity in previous studies (Kavalali and Monteggia, 2012; Williams and Schatzberg, 2016).”
Chung, C. (2013) · Molecules and Cells · doi:10.1007/s10059-013-0113-y · Cited by 31
“For example, a non-competitive NMDAR antagonist ketamine is currently under clinical evaluation for its therapeutic action in depressive disorders (for review, see Chung, 2012; Kavalali and Monteggia, 2012).”
BackgroundKinetic models for activation and modulation of NMDA receptor subtypes
Iacobucci, G. J., & Popescu, G. (2018) · Current Opinion in Physiology · doi:10.1016/j.cophys.2018.02.002 · Cited by 31
A key requirement for synaptic Reelin signaling in ketamine-mediated behavioral and synaptic action
Kim, J., Herz, J., Kavalali, E. T., & Monteggia, L. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103079118 · Cited by 30
Self-citationRapid treatments for depression: Endocannabinoid system as a therapeutic target
Sharafi, A., Pakkhesal, S., Fakhari, A., Khajehnasiri, N., & Ahmadalipour, A. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104635 · Cited by 31
Klotho protein: Its role in aging and central nervous system pathology
Бокша, И. С., Prokhorova, T. A., Savushkina, O. K., & Терешкина, Е. Б. (2017) · Biochemistry (Moscow) · doi:10.1134/s0006297917090024 · Cited by 30
“In addition to schizophrenia and epilepsy, with impaired function of glutamate trans porters, alteration in glutamate system activity con tributes to major depressive disorder [85].”
New Insights Into BDNF Signaling: Relevance to Major Depression and Antidepressant Action
Kerman, I. A. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12081053 · Cited by 31
“Recent work has also suggested that rapid antidepressant response following ketamine administration is mediated by BDNF signaling, a topic reviewed by Monteggia and Kavalali (11) in this issue of the Journal.”
BackgroundInfluentialStan, T. L., Alvarsson, A., Branzell, N., Sousa, V. C., & Svenningsson, P. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.39 · Cited by 30
Alten, B., Guzikowski, N. J., Zurawski, Z., Hamm, H. E., & Kavalali, E. T. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110255 · Cited by 27
Self-citationNona, C. N., Li, R., & Nóbrega, J. N. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.11.037 · Cited by 27
Stefanik, M. T., Milovanovic, M., Werner, C. T., Spainhour, J. C. G., & Wolf, M. E. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.02.012 · Cited by 26
Wang, C. S., Chanaday, N. L., Monteggia, L. M., & Kavalali, E. T. (2022) · eLife · doi:10.7554/elife.76008 · Cited by 25
Self-citationKetamine’s rapid and sustained antidepressant effects are driven by distinct mechanisms
Rawat, R., Tunc‐Ozcan, E., Dunlop, S. R., Tsai, Y., Li, F., Bertossi, R., Peng, C., & Kessler, J. A. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05121-6 · Cited by 26
“However, not all NMDA receptor antagonists reproduce ketamine’s behavioral effects [14–17], implicating additional mechanisms of action [18–22].”
Intravenous infusion of xenon-containing liposomes generates rapid antidepressant-like effects
Dandekar, M. P., Peng, T., McPherson, D. D., Quevedo, J., Soares, J. C., & Huang, S. L. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.03.011 · Cited by 25
Opioid sparing multimodal analgesia treats pain after head and neck microvascular reconstruction
Lee, T. S., Wang, L., Yi, D. I., Prasanna, P. D., & Kandl, C. (2019) · The Laryngoscope · doi:10.1002/lary.28402 · Cited by 25
“Ketamine has been implicated in decreasing inflammation and pain perception and may even have antidepressant effects.(10) Unique advantages include minimal hemodynamic effects (i.”
BackgroundMolecular pathways of ketamine: A systematic review of immediate and sustained effects on PTSD
Wellington, N. J., Bouças, A. P., Lagopoulos, J., Quigley, B. L., & Kuballa, A. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06756-4 · Cited by 25
“By comparing the results from rodent studies to human clinical trials, researchers can identify biomarkers and molecular targets influenced by ketamine, facilitating the development of more effective and personalised treatment strategies (Kavalali and Monteggia 2012).”
Subdissociative Ketamine Use in the Emergency Department
Nichols, K. A., & Paciullo, C. A. (2019) · Advanced Emergency Nursing Journal · doi:10.1097/tme.0000000000000222 · Cited by 24
Ren, L. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110910 · Cited by 23
“The rapid effect of ketamine as an antidepressant is widely believed to be mediated through glutamatergic transmission, which controls synaptic plasticity (Lener et al., 2017; Kavalali and Monteggia, 2012; Suzuki et al., 2021).”
BackgroundPlante, D. T., Goldstein, M. R., Landsness, E. C., Riedner, B. A., Guokas, J. J., Wanger, T., Tononi, G., & Benca, R. M. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.05.084 · Cited by 23
“…in MDD, such as sleep deprivation and ketamine, result in changes that reflect increases in synaptic strength, including increased slow wave amplitude and slope, as well as increased brain-derived neurotropic factor (Duncan, et al, 2012; Gorgulu and Caliyurt, 2009; Kavalali and Monteggia, 2012).”
BackgroundAnxiolytic drug discovery: What are the novel approaches and how can we improve them?
Stewart, A. M., & Kalueff, A. V. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.857309 · Cited by 22
“For example, growing evidence suggests that hallucinogenic drugs may have some clinical value in treating selected affective disorders, such as OCD [70,71], post-traumatic stress disorder [72,73] and depression [74-76].”
BackgroundHao, X., Zhu, X., Li, P., Lv, F., & Min, S. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.11.021 · Cited by 21
Structural Basis for the Recognition of Eukaryotic Elongation Factor 2 Kinase by Calmodulin
Lee, K., Alphonse, S., Piserchio, A., Tavares, C. D. J., Giles, D. H., Wellmann, R. M., Dalby, K. N., & Ghose, R. (2016) · Structure · doi:10.1016/j.str.2016.06.015 · Cited by 21
Rapid and Sustained Restoration of Astrocytic Functions by Ketamine in Depression Model Mice
Ma, X., Yang, S., Zhang, Z., Liu, L., Shi, W., Yang, S., Li, S., Cai, X., & Zhou, Q. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.03.068 · Cited by 21
Ketamine disrupts neuromodulatory control of glutamatergic synaptic transmission
Lür, G., Fariborzi, M., & Higley, M. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213721 · Cited by 21
“Acute doses of ketamine have been shown to produce rapid synaptic reorganization in the prefrontal cortex that coincides with antidepressant actions in rodent models [21, 38].”
BackgroundKlotho Sensitivity of the Neuronal Excitatory Amino Acid Transporters EAAT3 and EAAT4
Almilaji, A., Muñoz, C., Pakladok, T., Alesutan, I., Feger, M., Föller, M., Lang, U. E., Shumilina, E. V., & Lang, F. J. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070988 · Cited by 20
“Morover, recent clinical studies have demonstrated that a single subpsychotomimetic dose of ketamine, an ionotropic glutamatergic N-methyl-D-aspartate (NMDA) receptor antagonist, produces a rapid antidepressant response in patients with major depressive disorder, with effects lasting up to 2 weeks [67].”
BackgroundGagne, C., Piot, A., & Brake, W. G. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.797577 · Cited by 23
Zarate, C. A., & Machado‐Vieira, R. (2016) · Bipolar Disorders · doi:10.1111/bdi.12452 · Cited by 20
5-HT2A Receptors and BDNF Regulation: Implications for Psychopathology
Jaggar, M., & Vaidya, V. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-70474-6_17 · Cited by 19
Cai, M., Zhu, Y., Shanley, M. R., Morel, C., Ku, S. M., Zhang, H., Shen, Y., Friedman, A. K., & Han, M.-H. (2023) · Neurobiology of Stress · doi:10.1016/j.ynstr.2023.100565 · Cited by 18
“Recent studies have identified several rapidly acting antidepressant compounds that targeting glutamate or acetylcholine pathways, such as ketamine and scopolamine (Autry et al., 2011; Bagot et al., 2017; Drevets et al., 2013; Duman et al., 2016; Gerhard et al., 2016; Kavalali and Monteggia, 2012; Voleti et al., 2013;…”
Vibholm, A. K., Landau, A. M., Møller, A., Jacobsen, J., Vang, K., Munk, O. L., Orłowski, D., Sørensen, J. C. H., & Brooks, D. J. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20954928 · Cited by 20
“Finally, high blocking doses of ketamine lead to increased GABAergic activity and decreased glutamate levels(45) – another non-NMDAR pathway of ketamine action.(46) Wherever else S-ketamine might bind, its dominating and primary action is still non-competitive open IC blocking via binding to the NMDAR-IC PCP site when…”
BackgroundThe potential utility of some legal highs in CNS disorders
Davidson, C., & Schifano, F. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.07.010 · Cited by 18
“Their main pharmacological mechanism is NMDA receptor antagonism although there are other pharmacological effects (Kavalali and Monteggia, 2012).”
Scopolamine and Ketamine: Evidence of Convergence?
Monteggia, L. M., & Kavalali, E. T. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.08.011 · Cited by 18
Self-citationKetamine and other glutamate receptor modulators for depression in bipolar disorder in adults
Rendell, J. M., Shuttleworth, C., Jochim, J., Diamond, P. R., Brett, D., Amit, B. H., Hawton, K. E., McShane, R. H., & Cipriani, A. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011611 · Cited by 18
Rapid Antidepressant Activity of Ketamine Beyond NMDA Receptor
Hashimoto, K. (2017) · Springer eBooks · doi:10.1007/978-3-319-49795-2_4 · Cited by 17
Effects of ketamine on postoperative cognition: a scoping review
Brenna, C. T. A., He, X., Liu, D., Kaustov, L., Choi, S., & Orser, B. A. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2025.05.035 · Cited by 17
Promising new pharmacological targets for depression: The search for efficacy
Tsugiyama, L. E., de Moraes, R. C. M., Moraes, Y. A. C., & de Oliveira, J. F. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103804 · Cited by 17
Pervasive compartment-specific regulation of gene expression during homeostatic synaptic scaling
Colameo, D., Rajman, M., Soutschek, M., Bicker, S., von Ziegler, L., Bohacek, J., Winterer, J., Germain, P., Dieterich, C., & Schratt, G. M. (2021) · EMBO Reports · doi:10.15252/embr.202052094 · Cited by 16
“More-over, defects in synaptic scaling have been associated with the pathophysiology of several neurological diseases, e.g. autism (Rett syndrome), mental retardation (e.g. Fragile-X Syndrome) (Ramocki & Zoghbi, 2008), epilepsy (Swann & Rho, 2014) and mood disorders (Kavalali & Monteggia, 2012).”
Translational psychiatry—light at the end of the tunnel
Jones, K., Menniti, F. S., & Sivarao, D. V. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12725 · Cited by 16
Comprehensive view of suicide: A neuro-immune-endocrine approach
Ponce-Regalado, M. D., Becerril‐Villanueva, E., Maldonado-García, J. L., Moreno-Lafont, M. C., Martínez-Ramírez, G., Jacinto-Gutiérrez, S., Arreola, R., Sánchez-Huerta, K., de Oca, A. C.-M., López-Martínez, K. M., et al. (2025) · World Journal of Psychiatry · doi:10.5498/wjp.v15.i2.98484 · Cited by 16
Widman, A. J., & McMahon, L. L. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.05.001 · Cited by 15
Almeida-Corrêa, S., Czisch, M., & Wotjak, C. T. (2018) · Frontiers in Neural Circuits · doi:10.3389/fncir.2018.00042 · Cited by 15
“, 2006) or antidepressant-like effects in low doses (Kavalali and Monteggia, 2012).”
BackgroundShao, J., Meng, L., Yang, Z., Yu, P., Song, L., Gao, Y., Gong, M., Meng, C., & Shi, H. (2020) · NeuroReport · doi:10.1097/wnr.0000000000001415 · Cited by 14
Emnett, C. M., Li, H., Jiang, X., Benz, A. M., Boggiano, J., Conyers, S. B., Wozniak, D. F., Zorumski, C. F., Reichert, D. E. C., & Mennerick, S. J. (2016) · Scientific Reports · doi:10.1038/srep38808 · Cited by 14
Spontaneous neurotransmission: A form of neural communication comes of age
Kavalali, E. T. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24207 · Cited by 16
“To date, this work has revealed roles in regulation of synaptic network assembly and maturation as well as critical tasks in homeostatic forms of synaptic plasticity possibly underlying certain forms of behavior and response to neuropsychiatric treatments (Kavalali & Monteggia, 2012).”
BackgroundSelf-citationRaab‐Graham, K. F., Workman, E. R., Namjoshi, S. V., & Niere, F. (2016) · Brain Research · doi:10.1016/j.brainres.2016.04.020 · Cited by 13
“Upon BDNF binding, TrkB signals cascade to turn mTOR on (Kavalali and Monteggia, 2012, 2015; Takei et al., 2004).”
BackgroundMingardi, J., Ndoj, E., Bonifacino, T., Misztak, P., Bertoli, M., Via, L. L., Torazza, C., Russo, I., Milanese, M., Bonanno, G., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310814 · Cited by 13
LaGamma, C. T., Tang, W. W., Morgan, A. A., McGowan, J. C., Brachman, R. A., & Denny, C. A. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00404 · Cited by 13
“Given that ketamine had no significant effect on the number of Ki67+ cells in the HPC, we next quantified the effect of a higher dosage of ketamine on another principle marker for mitotic cells division in the rodent brain, 5-Bromo2′-deoxyuridine (BrdU; Gratzner, 1982; Kee et al., 2002).”
BackgroundTRPM7 functions in non-neuronal and neuronal systems: Perspectives on its role in the adult brain
Abumaria, N., Li, W., & Liu, Y. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.08.038 · Cited by 13
Xiong, X., Poulsen, M. H., Hussein, R. A., Nørager, N. G., & Strømgaard, K. (2014) · ChemMedChem · doi:10.1002/cmdc.201402278 · Cited by 13
Zhang, J., Niu, Z., Wang, T., Yu, L., Ren, X., Zhang, S., Zhu, Y., & Qi, D. (2025) · Perioperative Medicine · doi:10.1186/s13741-025-00567-z · Cited by 13
“The primary objective of this study was to assess whether low-dose esketamine can improve the quality of recovery in patients undergoing total laparoscopic hysterectomy via the QoR-40 questionnaire [15].”
A novel framework for ketamine-assisted couple therapy
Khalifian, C. E., Rashkovsky, K. T., Mitchell, E., Bismark, A. W., Wagner, A. C., & Knopp, K. C. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1376646 · Cited by 12
HCN channels: New targets for the design of an antidepressant with rapid effects
Luo, P., He, G., & Liu, D. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.11.081 · Cited by 12
Sun, Z., Yang, L., Zhao, L., Cui, R., & Yang, W. (2020) · Neural Plasticity · doi:10.1155/2020/8814531 · Cited by 12
Piserchio, A., Long, K. J., Lee, K., Kumar, E. A., Abzalimov, R. R., Dalby, K. N., & Ghose, R. (2021) · Protein Science · doi:10.1002/pro.4087 · Cited by 12
“Given the critical role of eEF-2K in cellular physiology, its aberrant regulation has been implicated in various diseases that include several cancers(24,25) and neurological disorders.(26,27) To aid in our long-term goal of obtaining a mechanistic understanding of the CaM-mediated activation of eEF-2K in atomic detai…”
BackgroundGálvez, V., Nikolin, S., Ho, K.-A., Alonzo, A., Somogyi, A. A., & Loo, C. K. A. (2016) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2016.10.012 · Cited by 11
“Although the mechanisms of ketamine's antidepressant effects are not yet fully understood, neural plasticity has been proposed to play a key role [4].”
BackgroundPiserchio, A., Will, N. E., Giles, D. H., Hajredini, F., Dalby, K. N., & Ghose, R. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.05.019 · Cited by 11
Tian, J., Xie, Y., Ye, S., Hu, Y., Feng, J., Li, Y., Lou, Z., Ruan, L., & Wang, Z. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151965 · Cited by 10
Su, T., Cheng, L., Tu, P., Chen, L., Lin, W., Li, C., Bai, Y., Tsai, S., & Chen, M. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116377 · Cited by 10
Lipman, A. G. (2010) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.3109/15360288.2010.529988 · Cited by 10
“(2) Benefit refers to the appreciation of the potential for marijuana and/or heroin to provide effective, affordable, and accessible treatment for refractory pain and other symptoms.”
In vivo imaging of CREB phosphorylation in awake-mouse brain
Ishimoto, T., Mano, H., & Mori, H. (2015) · Scientific Reports · doi:10.1038/srep09757 · Cited by 10
Guzman, D. D., Carreira, M. B., Friedman, A. K., Adachi, M., Neve, R. L., Monteggia, L. M., Han, M., Cowan, C. W., & Self, D. W. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.2828-16.2017 · Cited by 9
“…or therapeutic manipulation of NMDARs, although one could envision potential applications where long-term homeostatic compensation following relatively brief attenuation of NMDAR function would be advantageous (e.g., ketamine in treatment-resistant depression; Kavalali and Monteggia, 2012).”
BackgroundSelf-citationExisting and Novel Biological Therapeutics in Suicide Prevention
Griffiths, J. J., Zarate, C. A., & Rasimas, J. J. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.23021003 · Cited by 9
“The effect is thought to be mediated by molecular cascades that promote synaptic plasticity and dendritic spine maturation in key brain regions.(47) Ketamine is generally well tolerated at low doses, with the most common side effects being transient and limited to the infusion period (generally 40–60 minutes), includi…”
The interactive effects of ketamine and magnesium upon depressive-like pathology
Hayley, S. P., Razmjou, S., Litteljohn, D., Rudyk, C., Syed, S., Clarke, M., Pentz, R., & Dwyer, Z. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s111131 · Cited by 9
“2,19,37 Indeed, the hope is that a better understanding of the molecular and cellular pathways subserving ketamine’s antidepressant action will lead to the development of novel glutamatergic drugs that share with ketamine its mode of action/ antidepressant potential but not its unwanted effects.”
BackgroundAligeti, S., Quinones, M. P., & Salazar, R. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000146 · Cited by 9
Lee, K. K., Jeong, W., & Chae, M. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217768 · Cited by 8
“Its therapeutic applications have expanded to treatment-resistant depression and complex regional pain syndrome (CRPS), showing significant improvements in both pain relief and quality of life [46,47].”
Insulin and IGF signaling in the brain: multilevel regulation of synaptic and network homeostasis
Li, L., He, H., & Wang, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1793536 · Cited by 9
“Currently, a substantial body of literature indicates that pharmacological agents, including lithium (99), ketamine (100), IL-33 (101) and retinoic acid (102), target synaptic homeostatic plasticity to address neuropsychiatric disorders.”
Dimitrov, I. V., Harvey, M. G., Voss, L. J., Sleigh, J. W., Bickerdike, M. J., & Denny, W. A. (2020) · Molecules · doi:10.3390/molecules25122950 · Cited by 8
“It has often been stated, [3,4] and equally disputed [5], that the sedative analgaesic and psychotomimetic properties of ketamine are due to interaction with/inhibition of the NMDA receptor.”
BackgroundChen, M., Su, T., Li, C., Lin, W., Wu, H.-J., Tsai, S., Bai, Y., Mao, W., & Tu, P. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01735-2 · Cited by 8
“In addition, the main biological mechanism of ketamine is involved with an increase in synaptogenesis and BDNF levels, which is initiated by the antagonistic effect of N-methyl-D-aspartate receptors in γ-aminobutyric acid interneurons [35, 36].”
Regarding the Transpersonal Nature of Ketamine Therapy: An Approach to the Work
Becker, J. (2014) · International Journal of Transpersonal Studies · doi:10.24972/ijts.2014.33.2.151 · Cited by 8
“This may partially explain the neurological changes that resolve depression (Kavalali & Monteggia, 2012), but it is clear that ketamine’s effects as an antidepressant are unlike traditional medications.”
BackgroundStefanik, M. T., Sakas, C., Lee, D. M., & Wolf, M. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.032 · Cited by 8
“Spontaneous (minis) and evoked (action-potential dependent) glutamate transmission involve different vesicle populations and influence distinct postsynaptic compartments and signaling cascades (Kavalali, 2015; Kavalali and Monteggia, 2012; Sutton and Schuman, 2009).”
Synaptic basis of rapid antidepressant action
Kavalali, E. T., & Monteggia, L. M. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01898-6 · Cited by 7
Self-citationLysophosphatidic acid selectively modulates excitatory transmission in hippocampal neurons
Brandt, N., Battefeld, A., Suckau, O., Stadler, K., Singh, B., Zhang, P., Aoki, J., Chun, J. J. M., Henneberger, C., Grantyn, R., et al. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01458-y · Cited by 7
Maltbie, E. A., Gopinath, K., & Howell, L. L. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05204-4 · Cited by 7
“2006), and there are corresponding antidepressant-like effects in rodent behavioral models that are mediated by neuroplastic changes in the PFC (Kavalali and Monteggia 2012; Li et al. 2010).”
BackgroundKwon, H., Jeon, J., Cho, E., Moon, S., Park, A. Y., Kwon, H. J., Kwon, K. J., Ryu, J. H., Shin, C. Y., Yi, J. H., et al. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110431 · Cited by 6
Scherbaum, U. B. N. (2014) · Journal of Alcoholism and Drug Dependence · doi:10.4172/2329-6488.1000198 · Cited by 6
“iii) Increased neurotrophin (BDNF, NGF) levels after acute administration [44,45] and decreased neurotrophin levels during prolonged intake [14,46].”
BackgroundLong-Term Adaptive Changes Induced by Antidepressants: From Conventional to Novel Therapies
Mnie‐Filali, O., Abrial, E., Lambás‐Señas, L., & Haddjeri, N. (2013) · InTech eBooks · doi:10.5772/54553 · Cited by 6
“Recent reports using subpsychomimetic doses of ketamine, an ionotropic glutamatergic N-methyl-D-aspartate (NMDA) receptor antagonist, showed a rapid AD response in MDD subjects [198], which is hypothesized to be mediated by i) lower Glx/glutamate ratio in the PFC associated with reductions in glial cells in the same r…”
BackgroundPsicofarmacología del suicidio: un análisis crítico
Martínez-Aguayo, J. C., Arancibia, M., & Hernán Silva, I. (2015) · Revista chilena de neuro-psiquiatría · doi:10.4067/s0717-92272015000200008 · Cited by 8
Metadata
- Authors
- Kavalali, E. T., & Monteggia, L. M.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Venue
- American Journal of Psychiatry
- Published
- 2012-11
- Volume
- 169
- Issue
- 11
- Pages
- 1150-1156
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2124203952
- Cited by
- 258
- References
- 48
- Citations by year
- 2026: 11 · 2025: 17 · 2024: 10 · 2023: 11 · 2022: 16 · 2021: 18 · 2020: 11 · 2019: 19 · 2018: 15 · 2017: 17 · 2016: 20 · 2015: 27 · 2014: 31 · 2013: 31 · 2012: 2
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH 070727, R01MH066198, MH-066198, R01MH070727)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, major depressive disorder, NMDA receptor antagonism, homeostatic plasticity, eEF2K, eEF2 phosphorylation, brain-derived neurotrophic factor, glutamatergic neurotransmission, presynaptic neurotransmitter release, rapid-acting antidepressants
- MeSH terms
- Animals, Antidepressive Agents, Brain, Disease Models, Animal, Humans, Ketamine, Synaptic Transmission, Neuronal Plasticity, Synapses, Synaptic Vesicles, Signal Transduction, Receptors, N-Methyl-D-Aspartate, Neurotransmitter Agents, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.